A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases

Breast Cancer Research and Treatment

Volumn 48, Issue 1, 1998, Pages 21-32

  Tsuda, Hitoshi ^a   Sakamaki, Chinami ^a   Tsugane, Shoichiro ^a   Fukutomi, Takashi ^b   Hirohashi, Setsuo ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

c erbB 2; Loss of heterozygosity; Node positive breast cancer; p53; Prognostic factors; Stratification

Indexed keywords

HORMONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CHROMOSOME 16P; CHROMOSOME 16Q; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 18Q; DIAGNOSTIC VALUE; FEMALE; GENE AMPLIFICATION; HETEROZYGOSITY LOSS; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE C ERB; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE;

EID: 0031882057     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005977630830     Document Type: Article

References (54)

1. Seeger RC, Brodeur RC, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D: Multiple copies of the N-myc oncogene in neuroblastomas correlates with advanced disease stage. N Engl J Med 313: 1111-1116, 1985
2. Wong AJ, Ruppert JM, Eggleston J, Hamilton SR, Baylin SB, Vogelstein B: Gene amplification of c-myc and N-myc in small cell carcinoma of the lung. Science 233: 461-464, 1986
3. Yokota J, Yamamoto T, Toyoshima K, Terada M, Sugimura T, Battifora H, Cline MJ: Amplification of c-erbB-2 oncogene in human adenocarcinoma in vivo. Lancet i: 765-766, 1986
4. Kitagawa Y, Ueda M, Ando N, Shinozaka Y, Shimizu N. Abe O: Significance of int-2/hst-1 coamplification as a prognostic factor in patients with esophageal squamous carcinoma. Cancer Res 51: 1504-1508, 1991
5. Riou G, Favre M, Jeannel D, Bourhis J, Le Doussal V, Orth G: Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet 335: 1171-1174, 1990
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987
7. Wright C, Angus B, Nicholson AL, Sainsbury JRC, Cairns J, Gullick WJ, Kelly P, Harris AL, Home CHW: Expression of c-erbB-2 oncoprotein: a prognostic factor in human breast cancer. Cancer Res 49: 2087-2090, 1989
8. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsuganc S, Yamamoto H, Miyajima N, Toyoshima K, Yamamoto T, Yokota J, Yoshida T, Sakamoto H, Terada M, Sugimura T: Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res 49: 3104-3108, 1989
9. Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51: 944-948, 1991
10. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K, Hirohashi S: Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 82: 835-840, 1991
11. Thor A, Smith DHM II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen L-C, Mayall BH, Smith HS: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84: 845-855, 1992
12. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206, 1993
13. Lipponen P, Ji H, Aaltomaa S, Syrjänen S, Syrjänen K: p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 55: 51-56, 1993
14. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U: The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994
15. Bièche I, Champème MH, Matifas F, Hacène K, Callahan R, Lidereau R: Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet 339: 139-143, 1992
16. Winqvist R, Hampton GM, Mannermaa A, Blance G, Alavaikko M, Kiviniemi H, Taskinen PJ, Evans GA, Wright FA, Newsham I, Cavenee WK: Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res 55: 2660-2664, 1995
17. Chen L-C, Neubauer A, Kurisu W, Waldman FM, Ljung B-M, Goodson W III, Goldman ES, Moor D II, Balazs M, Liu E, Mayall BH, Smith HS: Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary breast cancer. Proc Natl Acad Sci USA 88: 3847-3851, 1991
18. Merlo GR, Venesio T, Bernardi A, Canale L, Gaglia P, Lauro D, Cappa APM, Callahan R, Liscia DS: Loss of heterozygosity on chromosome 17p13 in breast carcinomas identifies tumors with high proliferation index. Am J Pathol 140: 215-223, 1992
19. Tsuda H, Fukutomi T, Hirohashi S: Pattern of gene alterations in intraductal breast neoplasms associated with histological type and grade. Clin Cancer Res 1: 261-267, 1995
20. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF. Linnoila RI: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7: 743-749, 1992
21. Tsuda H, Hirohashi S: Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J Cancer 57: 498-503, 1994
22. Histological Typing of Breast Tumours. International histological classification of tumours, no. 2. World Health Organization, Geneva, 1981, p 18-22
23. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabc S, Terada M, Yamamoto H: Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. Cancer 65: 1794-1800, 1990
24. Fukutomi T, Akashi S, Nanasawa T, Yamamoto H: Adjuvant six cycles of high-dose adriamycin, cyclophosphamide, methotrexate, 5-fluorouracil (ACMF) vs. 12 cycles of low-dose ACMF with tamoxifen for premenopausal, node positive breast cancer patients: results of a prospective randomized study. J Surg Oncol 60: 242-246, 1995
25. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning. A Laboratory Manual. 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989, p 9.16-9.19, p 9.31-9.55
26. Julier C, Nakamura Y, Lathrop M, O'Connell P, Leppert M, Mohandas T, Lalouel J-M, White R: A primary map of 24 loci on human chromosome 16. Genomics 6: 419-427, 1990
27. Assum G, Griese E-U, Horst J: Detection of a restriction site polymorphism within the human alpha-globin gene complex. Hum Genet 69: 144-146, 1985
28. Hyland VJ, Grist G, Sutherland GR: Restriction fragment length polymorphisms detected by anonymous DNA probes mapped to defined intervals of human chromosome 16. Hum Genet 79: 277-279, 1988
29. 2 gene. Nature 309: 131-135, 1984
30. Wullich B, Natt E, Wienker TF, Scherer G: A BamHI RFLP at the human tyrosine aminotransferase (TAT) gene locus at 16q. Nucleic Acids Res 17: 3331, 1989
31. Bufton L, Mohandas TK, Magenis RE, Sheehy R, Bestwick RK, Litt M: A highly polymorphic locus on chromosome 16q revealed by a probe from a chromosome-specific cosmid library. Hum Genet 74: 425-431, 1986
32. Murray AM, Drobetsky E, Arrand JE: Cloning the complete human adenine phosphoribosyl transferase gene. Gene 31: 233-240, 1984
33. Kondoleon S, Vissing H, Luo XY, Magenis RE, Kellogg J, Litt M: A hypervariable RFLP on chromosome 17p13 defined by an arbitrary single copy probe p144-D6. Nucleic Acids Res 15: 10605, 1987
34. Nakamura Y, Lathrop M, O'Connell P, Leppert M, Barker D. Wright E, Skolnick M, Kondoleon S, Litt M, Lalouel J-M, White R: A mapped set of DNA markers for human chromosome 17. Genomics 2: 302-309, 1988
35. Barker D, Wright E, Nguyen K, Cannon L, Fain CP, Goldgar D, Bishop DT, Carey J, Baty B, Kivlin J, Willard H, Waye JS, Greig G, Leinward L, Nakamura Y, O'Connell P, Leppert M, Lalouel J-M, White R, Skolnick M: Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science 236: 1110-1112, 1987
36. Marlhens F, Delattre O, Bernard A, Olschwang S, Dutrillaux B, Thomas G: RFLP identified by the anonymous DNA segment OL VII E10 at 18q21.3 (HGM no. D18S8). Nucleic Acids Res 15: 1348, 1987
37. Delattre O, Bernard A, Marlhens F, Monpezat J-P, Dutrillaux B, Thomas G: RFLP identified by the anonymous DNA segment OL VII A8 at 18q11 (HGM no D18S7). Nucleic Acids Res 15: 1343, 1987
38. Nishisho I, Miki T, Tateishi H, Takai S, Motomura K, Nakura J, Kumahara Y, Mori T, Honjo T: Isolation of DNA clones revealing restriction fragment length polymorphisms in the human genome. Jpn J Hum Genet 31: 249-258, 1986
39. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 319: 230-234, 1986
40. Casey G, Smith R, McGillivray D, Peters G, Dickson C: Characterization and chromosome assignment of human homolog of int-2, a potential proto-oncogene. Mol Cell Biol 6: 502-510, 1986
41. Yamada Y, Yoshida T, Hayashi K, Sekiya T, Yokota J, Hirohashi S, Nakatani K, Nakano H, Sugimura T, Terada M: p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. Cancer Res 51: 5800-5805, 1991
42. Tsuda H, Callen DF, Fukutomi T, Nakamura Y, Hirohashi S: Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespectively of differences in phenotype and extent of spread. Cancer Res 54: 513-517, 1994
43. Tsuda H, Iwaya K, Fukutomi T, Hirohashi S: p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn J Cancer Res 84: 394-401, 1993
44. Iwaya K, Tsuda H, Fukutomi T, Tsugane S, Suzuki M, Hirohashi S: Histologic grade and p53 immunoreaction as indicators of early recurrence of node-negative breast cancer. Jpn J Clin Oncol 27: 6-12, 1997
45. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
46. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Br J Cancer 35: 1-39, 1997
47. Cox DR: Regression models and life-tables. J Roy Stat Soc 34: 187-220, 1972
48. Berger MS, Locher GW, Sauer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48: 1238-1243, 1988
49. Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Zambetti M, Veronesi U: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5: 95-115, 1985
50. Mouridsen HT: Adjuvant systemic therapy in breast cancer. Eur J Cancer 29 (A): 595-598, 1993
51. Early breast cancer trialists' collaborative group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1-15, 71-85, 1992
52. Coombes RC, Bliss JM, Wils J, Morvan F, Espié M, Amadori D, Gambrosier P, Richards M, Aapro M, Villar-Grimart A, McArdle B, Pérez-López FR, Vassilopoulos R, Pinto Ferreira E, Chilvers CED, Coombes G, Woods EM, Marty M: Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. J Clin Oncol 14: 35-45, 1996
53. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260-1266, 1994; 331: 211, 1994
54. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260-1266, 1994; 331: 211, 1994